The Animal Imaging Core provides a wide array of non-invasive, high resolution quantitative imaging-based capabilities for metabolic and genetic characterization of tumors and their microenvironment. Among the critical scientific applications of small-animal imaging by MSKCC investigators are: phenotypic screening of tumor incidence, progression and therapy-induced regression in xenograft models and transgenic/knock-out models; assessment of trafficking of cancer cells, stem cells, and immune effector cells in vivo; evaluation of trans-gene expression, development, testing, and validation of targeted therapies (i.e. pharmacodynamics); and detection and localization of tumor hypoxia and re-oxygenation. These capabilities are broadly applicable to the fundamental mission of the Center in areas such as molecular imaging, assessment of therapeutic response, and drug development. The services provided by the Animal Imaging Core has supported the research of 65 investigators in the past year. During the past grant period the work of the Core has contributed to 370 publications of researchers from 9 research programs. As part of a major expansion and modernization of MSKCC's infrastructure, the Imaging Core has been consolidated and re-located to the Zuckerman Research Center's vivarium. This area provides enhanced biosecurity and functionality and houses the R4 and Focus 120 microPET, ivis 100 opfical imaging system, microCATII, microCT, NanoSPECT/CT Plus, SPECT-CT, Maestro, FMT 2500 near-Infrared fluorescence tomography system, and Vevo 2100 ultrasound system. The existing Ivis 100 optical imaging system remains at the Rockefeller Research Laboratory, supporting investigators In that building. A new high precision microirradiator, X-RAD, for rodent tumors and other structures was installed in 2012. The Core's 4.7T and 7.0T Brucker USR systems have also been moved to the Vivarium. The Core has provided critical support for the development and characterization of mouse models for human cancer. For example, models for glioma driven by PDGF-B signaling and anaplastic thyroid tumors driven by inducible mutant BRAF have been extensively characterized and examined for therapeutic responses using the imaging resources of the Core.
The Animal Imaging Core Provides non-invasive, high resolution quantitative imaging-based capabilities for metabolic and genetic characterization of tumors and their microenvironment. These capabilities which are broadly applicable to the fundamental mission of the Center in such diverse and important space areas as molecular imaging, assessment of treatment response, and drug development.
|Basaraba, Cale N; Westhoff, Carolyn L; Pike, Malcolm C et al. (2017) Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception 95:398-404|
|Hernandez, Jonathan M; Beylergil, Volkan; Goldman, Debra A et al. (2017) Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Ann Surg :|
|Argani, Pedram; Kao, Yu-Chien; Zhang, Lei et al. (2017) Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues. Am J Surg Pathol 41:1702-1712|
|Moore, Kathleen N; Martin, Lainie P; O'Malley, David M et al. (2017) Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 35:1112-1118|
|Lee, Ser Yee; Goh, Brian K P; Sadot, Eran et al. (2017) Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Ann Surg Oncol 24:202-210|
|Hyman, David M; Taylor, Barry S; Baselga, José (2017) Implementing Genome-Driven Oncology. Cell 168:584-599|
|Li, Gang G; Somwar, Romel; Joseph, James et al. (2017) Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clin Cancer Res 23:2981-2990|
|Bhagat, Tushar D; Zou, Yiyu; Huang, Shizheng et al. (2017) Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer. J Biol Chem 292:837-846|
|Prieto-Granada, Carlos N; Zhang, Lei; Antonescu, Cristina R et al. (2017) Primary cutaneous adenoid cystic carcinoma with MYB aberrations: report of three cases and comprehensive review of the literature. J Cutan Pathol 44:201-209|
|He, Mu; Agbu, Stephanie; Anderson, Kathryn V (2017) Microtubule Motors Drive Hedgehog Signaling in Primary Cilia. Trends Cell Biol 27:110-125|
Showing the most recent 10 out of 7561 publications